<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24875055</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>5</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved "knob" region of VP3 protein.</ArticleTitle><Pagination><StartPage>e2895</StartPage><MedlinePgn>e2895</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2895</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0002895</ELocationID><Abstract><AbstractText>Hand, foot and mouth disease caused by enterovirus 71(EV71) leads to the majority of neurological complications and death in young children. While putative inactivated vaccines are only now undergoing clinical trials, no specific treatment options exist yet. Ideally, EV71 specific intravenous immunoglobulins could be developed for targeted treatment of severe cases. To date, only a single universally neutralizing monoclonal antibody against a conserved linear epitope of VP1 has been identified. Other enteroviruses have been shown to possess major conformational neutralizing epitopes on both the VP2 and VP3 capsid proteins. Hence, we attempted to isolate such neutralizing antibodies against conformational epitopes for their potential in the treatment of infection as well as differential diagnosis and vaccine optimization. Here we describe a universal neutralizing monoclonal antibody that recognizes a conserved conformational epitope of EV71 which was mapped using escape mutants. Eight escape mutants from different subgenogroups (A, B2, B4, C2, C4) were rescued; they harbored three essential mutations either at amino acid positions 59, 62 or 67 of the VP3 protein which are all situated in the "knob" region. The escape mutant phenotype could be mimicked by incorporating these mutations into reverse genetically engineered viruses showing that P59L, A62D, A62P and E67D abolish both monoclonal antibody binding and neutralization activity. This is the first conformational neutralization epitope mapped on VP3 for EV71.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kiener</LastName><ForeName>Tanja K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, Singapore, Republic of Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, Singapore, Republic of Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, Singapore, Republic of Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Vincent Tak Kwong</ForeName><Initials>VT</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwang</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, Singapore, Republic of Singapore; Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>5</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24875055</ArticleId><ArticleId IdType="pmc">PMC4038473</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0002895</ArticleId><ArticleId IdType="pii">PNTD-D-13-01789</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chan KP, Goh KT, Chong CY, Teo ES, Lau G, et al. (2003) Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 9: 78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, et al. (1999) Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 18 (12) 1092&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">10608631</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum LC, Wong KT, Lam SK, Chua KB, Goh AY (1998) Neurogenic pulmonary oedema and enterovirus 71 encephalomyelitis. Lancet 352: 1391.</Citation><ArticleIdList><ArticleId IdType="pubmed">9802304</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, et al. (1999) Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 354: 1682&#x2013;1686.</Citation><ArticleIdList><ArticleId IdType="pubmed">10568570</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Ren L, Xiong Z, Li J, Xiao Y, et al. (2009) Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol 47: 2351&#x2013;2352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Bible JM, Pantelidis P, Chan PK, Tong CY (2007) Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol 17 (6) 371&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487831</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J (2008) Enterovirus 71 infection: a new threat to global public health? Lancet Neurol 7: 868&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128195</ArticleId><ArticleId IdType="pubmed">18848307</ArticleId></ArticleIdList></Reference><Reference><Citation>Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, et al. (2011) Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 29: 4829&#x2013;4838.</Citation><ArticleIdList><ArticleId IdType="pubmed">21550375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Liu L, Zhao H, Wang J, Liao Y, et al. (2011) Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 29: 6269&#x2013;6275.</Citation><ArticleIdList><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Devi S, Cardosa MJ, Wong KT (2009) Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 84: 661&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, et al. (2012) Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 30 (7) 1305&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, et al. (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26 (15) 1855&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng FY, Li JX, Li XL, Chu K, Zhang YT, et al. (2012) Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: An open label, phase 1 clinical trial. Hum Vaccin Immunother 8: 668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">22634437</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolpe AB, Kiener TK, Grotenbreg GM, Kwang J (2012) Display of enterovirus 71 VP1 on baculovirus as a type II transmembrane protein elicits protective B and T cell responses in immunized mice. Virus Res 168: 64&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">22728446</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Chang KC, Kao CM, Chang SP, Tung YY, et al. (2009) Lymphocyte and antibody responses reduce enterovirus 71 lethality in mice by decreasing tissue viral loads. J Virol 83: 6477&#x2013;6483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2698549</ArticleId><ArticleId IdType="pubmed">19386699</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, et al. (2012) Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 30 (22) 3295&#x2013;3303.</Citation><ArticleIdList><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, et al. (2012) A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19 (4) 424&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG (2012) Crystal structure of human enterovirus 71. Science 336 (6086) 1274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, et al. (2010) Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol 84 (7) 3339&#x2013;3350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838098</ArticleId><ArticleId IdType="pubmed">20089660</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallansch M RR (2007) Enterovirus: polioviruses, coxsackieviruses, echoviruses and newer enteroviruses. in: H.P. Knipe DM, Griffin DE et al... editors. Fields Virology. Philadelphia: Lippincott Williams &amp; Wilkins: p. 839&#x2013;893.</Citation></Reference><Reference><Citation>Herrero LJ, Lee CS, Hurrelbrink RJ, Chua BH, Chua KB, et al. (2003) Molecular epidemiology of enterovirus 71 in peninsular Malaysia, 1997&#x2013;2000. Arch Virol 148 (7) 1369&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pubmed">12827466</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P, Lindsay K, Perera D, Chan HM, Chan KP, et al. (2001) Phylogenetic analysis of enterovirus 71 strains isolated during linked epidemics in Malaysia, Singapore, and Western Australia. J Virol 75 (16) 7732&#x2013;7738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC115010</ArticleId><ArticleId IdType="pubmed">11462047</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Chow VT, Chan KP, Ling AE, Poh CL (2000) RT-PCR, nucleotide, amino acid and phylogenetic analyses of enterovirus type 71 strains from Asia. J Virol Methods 88 (2) 193&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">10960707</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding NZ, Wang XM, Sun SW, Song Q, Li SN, et al. (2009) Appearance of mosaic enterovirus 71 in the 2008 outbreak of China. Virus Res 145 (1) 157&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">19540282</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Li C, He D, Cheng T, Ge S, et al. (2012) Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. Vaccine 31 (2) 425&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">23088887</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, et al. (2009) Reemergence of Enterovirus 71 in 2008 in Taiwan: Dynamics of Genetic and Antigenic Evolution from 1998 to 2008. J Clin Microbiol 47 (11) 3653&#x2013;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772620</ArticleId><ArticleId IdType="pubmed">19776232</ArticleId></ArticleIdList></Reference><Reference><Citation>
Huang M-L, Chiang P-S, Chia M-Y, Luo S-T, Chang L-Y, et al. (2013) Cross-reactive Neutralizing Antibody Responses to Enterovirus 71 Infections in Young Children: Implications for Vaccine Development. PLoS Negl Trop Dis
7 (2) e2067
doi:10.1371/journal.pntd.0002067
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002067</ArticleId><ArticleId IdType="pmc">PMC3573098</ArticleId><ArticleId IdType="pubmed">23459633</ArticleId></ArticleIdList></Reference><Reference><Citation>
Huang YP, Lin TL, Hsu LC, Chen YJ, Tseng YH, et al. (2010) Genetic diversity and C2-like subgenogroup strains of enterovirus 71, Taiwan, 2008. Virol J
7: 277
doi: 10.1186/1743-422X-7-277
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-277</ArticleId><ArticleId IdType="pmc">PMC2975644</ArticleId><ArticleId IdType="pubmed">20959020</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Lin TY, Chiang PS, Li WC, Luo ST, et al. (2010) An investigation of epidemic enterovirus 71 infection in Taiwan, 2008: clinical, virologic, and serologic features. Pediatr Infect Dis J 29 (11) 1030&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20543760</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim XF, Jia Q, Khong WX, Yan B, Premanand B, et al. (2012) Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One 7 (1) e29751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261156</ArticleId><ArticleId IdType="pubmed">22279543</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD, Ferguson M, Evans DM, Almond JW, Icenogle JP (1986) Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol 67 (Pt 7) 1283&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pubmed">2425046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahnemann HG (1975) Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Arch Virol 47 (1) 47&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">167679</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama WM (2001) Production of monoclonal antibodies. Curr Protoc Cell Biol Chapter 16 Unit 16 1.</Citation><ArticleIdList><ArticleId IdType="pubmed">18228333</ArticleId></ArticleIdList></Reference><Reference><Citation>LAVER WG, AIR GM, WEBSTER RG, GERHARD W, WARD CW, et al. (1979) Antigenic drift in type A influenza virus: Sequence differences in the hemagglutinin of Hong Kong (H3N2) variants selected with monoclonal hybridoma antibodies. Virology 98: 226&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">90425</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Kiener TK, Kwang J (2012) RNA polymerase I-driven reverse genetics system for enterovirus 71 and its implications for vaccine production. Virol J 9: 238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493273</ArticleId><ArticleId IdType="pubmed">23072515</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, et al. (2012) A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol 86 (4) 2121&#x2013;2131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener TK, Jia Q, Lim XF, He F, Meng T, et al. (2012) Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein. Virol J 9: 55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307493</ArticleId><ArticleId IdType="pubmed">22361222</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, et al. (2007) Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 125 (1) 61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Cifuente JO, Ashley RE, Conway JF, Makhov AM, et al. (2013) A strain-specific epitope of Enterovirus 71 identified by cryoEM of the complex with Fab from neutralizing antibody. J Virol Nov;87 (21) 11363&#x2013;11370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807339</ArticleId><ArticleId IdType="pubmed">23946455</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Poh CL, Chow VT (2002) Complete sequence analyses of enterovirus 71 strains from fatal and non-fatal cases of the hand, foot and mouth disease outbreak in Singapore (2000). Microbiol Immunol 46 (11) 801&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12516778</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadnick E, Dan M, Sadeghi A, Chantler JK (2004) Attenuating mutations in coxsackievirus B3 map to a conformational epitope that comprises the puff region of VP2 and the knob of VP3. J Virol 78 (24) 13987&#x2013;14002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC533932</ArticleId><ArticleId IdType="pubmed">15564506</ArticleId></ArticleIdList></Reference><Reference><Citation>Page GS, Mosser AG, Hogle JM, Filman DJ, Rueckert RR, et al. (1988) Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J Virol 62 (5) 1781&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC253228</ArticleId><ArticleId IdType="pubmed">2451757</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry B, Mosser AG, Colonno RJ, Rueckert RR (1986) Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14. J Virol 57 (1) 246&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC252721</ArticleId><ArticleId IdType="pubmed">2416951</ArticleId></ArticleIdList></Reference><Reference><Citation>Ping LH, Jansen RW, Stapleton JT, Cohen JI, Lemon SM (1988) Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus. Proc Natl Acad Sci U S A 85 (21) 8281&#x2013;8285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC282413</ArticleId><ArticleId IdType="pubmed">2460866</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray MG, Kuhn RJ, Arita M, Kawamura N, Nomoto A, et al. (1988) Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys. Proc Natl Acad Sci U S A 85: 3203&#x2013;3207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280172</ArticleId><ArticleId IdType="pubmed">2834736</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore L, Ridolfi B, Genovese D, Buttinelli G, Lucioli S, et al. (1997) Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies. J Virol 71 (9) 6905&#x2013;6912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191973</ArticleId><ArticleId IdType="pubmed">9261417</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttinelli G, Ruggeri FM, Marturano J, Novello F, Donati V, et al. (2001) Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice. Virology 281 (2) 265&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">11277698</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, et al. (2011) Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 29: 4362&#x2013;4372.</Citation><ArticleIdList><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabakaran M, Prabhu N, He F, Hongliang Q, Ho HT, et al. (2009) Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS One 4: e5672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2682562</ArticleId><ArticleId IdType="pubmed">19478856</ArticleId></ArticleIdList></Reference><Reference><Citation>Meulen JT, Brink ENVD, Poon LLM, Marissen WE, Leung CSW, et al. (2006) Human monoclonal antibody combination against SARS Coronavirus: synergy and coverage of escape mutants. PLos Med 3 (7) e237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1483912</ArticleId><ArticleId IdType="pubmed">16796401</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold K, Bordoli L, Kopp J, Schwede T (2006) The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling. Bioinformatics 22: 195&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">16301204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiefer F, Arnold K, K&#xfc;nzli M, Bordoli L, Schwede T (2009) The SWISS-MODEL Repository and associated resources. Nucleic Acids Research 37: D387&#x2013;D392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2686475</ArticleId><ArticleId IdType="pubmed">18931379</ArticleId></ArticleIdList></Reference><Reference><Citation>Guex N, Peitsch MC, Schwede T (2009) SWISS-MODEL and Swiss PdbViewer. Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective. Electrophoresis 30 (S1) S162&#x2013;S173.</Citation><ArticleIdList><ArticleId IdType="pubmed">19517507</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>